皮肤鳞状细胞癌分期与监测影像共识指南
多学科专家采用德尔菲法,经3轮调查形成局部皮肤鳞状细胞癌分期与监测影像的共识建议。45名专家完成全部轮次,共识定义为同意率≥80%,近共识为70%至79%。共识为转移风险≥15%的肿瘤提供影像框架,CT是淋巴结分期与监测首选。
要点
- 转移风险≥15%的皮肤鳞癌推荐分期与监测影像。
- CT为淋巴结分期和监测首选,分别获84%和78%支持。
- 监测影像至少持续2年,近共识支持至少3年。
核心结论
- 本德尔菲共识为局部皮肤鳞状细胞癌的影像分期与监测提供标准化框架,可供未来指南参考。
研究设计与样本
- 多学科专家组德尔菲共识,2025年1月至6月完成3轮迭代调查,2025年2月至2026年1月分析数据。
- 纳入资格包括既往5年至少1至2篇皮肤鳞癌论文、参与相关临床试验、每月治疗至少3例皮肤鳞癌、或临床实践≥5年。
- 共识定义为同意率≥80%,近共识为70%至79%。
诊断标准与关键数值
- 推荐对转移风险至少15%的皮肤鳞癌进行分期与监测。
- 推荐分期与监测影像的指征:怀疑转移、骨侵犯、超出皮下脂肪的侵犯、粗大神经侵犯、直径≥4cm。
- 推荐分期与监测影像的指征:低分化组织学合并以下任一情况,直径≥2cm、淋巴血管侵犯伴皮下脂肪侵犯、或淋巴血管侵犯伴小神经周围侵犯。
- CT为淋巴结分期(38人,84%)和监测(35人,78%)首选影像方式。
- 监测影像持续时间:共识为至少2年,近共识为至少3年。
临床应用与阅片要点
- 阅片时关注皮肤鳞癌的淋巴结转移征象,CT作为首选检查方式。
- 对于直径≥4cm或存在骨侵犯、深部侵犯的皮肤鳞癌,应主动提示分期影像需求。
- 低分化肿瘤合并淋巴血管侵犯时,即使直径2cm也需警惕并建议影像监测。
- 影像监测需覆盖至少2年,报告可提示临床持续监测的时间框架。
局限性
- 共识由专家意见构成,并非基于诊断准确性研究的定量证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
IMPORTANCE: There is no consensus on staging and surveillance imaging for cutaneous squamous cell carcinoma (CSCC). Although imaging has been shown to affect management, broad recommendations from the National Comprehensive Cancer Network have led to variability in clinical practice.
OBJECTIVE: To develop multidisciplinary consensus recommendations on the use of staging and surveillance imaging of localized CSCC.
EVIDENCE REVIEW: A multidisciplinary expert panel across academic and clinical practice settings convened a Delphi consensus, with 3 iterative survey rounds from January to June 2025. Data were analyzed from February 2025 to January 2026. Eligibility defined by at least 1 to 2 CSCC publications during the previous 5 years, involvement in a relevant clinical trial, experience treating at least 3 patients monthly with CSCC, and/or 5 years or longer of clinical practice. Fifty-four experts were invited and 45 (83%) completed all 3 rounds and were included in the final analysis. Structured Delphi surveys evaluated clinical scenarios, imaging modalities, and surveillance strategies for CSCC. Consensus and near-consensus recommendations were generated, defined as 80% or greater and 70% to 79% agreement, respectively.
FINDINGS: The 45 participants (21 female individuals [47%] and 24 male individuals [53%]; 14 Asian individuals [31%], 1 multiracial individual [2%], and 30 White individuals [67%]) consisted of dermatology (15 [33%]), medical oncology (7 [16%]), radiation oncology (9 [20%]), radiology (9 [20%]), surgery (3 [7%]), and otolaryngology specialists (2 [4%]). The Delphi panel recommended staging and surveillance for CSCCs with at least a 15% risk of metastasis. Consensus or near consensus was reached to recommend staging and surveillance imaging for tumors with a concern for metastasis, bone invasion, invasion beyond subcutaneous fat, large-caliber nerve invasion, or a diameter of 4 cm or larger or the combination of tumors with poorly differentiated histology and any of the following: diameter of 2 cm or larger, lymphovascular invasion and subcutaneous fat invasion, or lymphovascular invasion and small-caliber perineural invasion. Computed tomography imaging was the preferred modality for nodal staging (38 [84%]) and surveillance (35 [78%]). For surveillance duration, consensus was reached to provide imaging for at least 2 years, and near consensus was reached for at least 3 years.
CONCLUSIONS AND RELEVANCE: This study provides an expert consensus-based framework to standardize imaging in localized CSCC that may inform future guidelines.
引用
- Kassamali, Schoenfeld, Sethi, et al. Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2026. PMID: 42418212. doi:10.1001/jamadermatol.2026.2163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。